keyword
MENU ▼
Read by QxMD icon Read
search

baclofen AND alcohol

keyword
https://www.readbyqxmd.com/read/29665351/neuroendocrine-response-to-gaba-b-receptor-agonism-in-alcohol-dependent-individuals-results-from-a-combined-outpatient-and-human-laboratory-experiment
#1
Mehdi Farokhnia, Mikela B Sheskier, Mary R Lee, April N Le, Erick Singley, Sofia Bouhlal, Timmy Ton, Zhen Zhao, Lorenzo Leggio
Gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the nervous system, plays an important role in biobehavioral processes that regulate alcohol seeking, food intake, and stress response. The metabotropic GABA-B receptor has been investigated as a potential therapeutic target for alcohol use disorder, by using orthosteric agonists (e.g., baclofen) and positive allosteric modulators. Whether and how pharmacological manipulation of the GABA-B receptor, in combination with alcohol intake, may affect feeding- and stress-related neuroendocrine pathways remains unknown...
April 14, 2018: Neuropharmacology
https://www.readbyqxmd.com/read/29651507/efficacy-and-side-effects-of-baclofen-and-the-novel-gaba-b-receptor-positive-allosteric-modulator-cmppe-in-animal-models-for-alcohol-and-cocaine-addiction
#2
Valentina Vengeliene, Tatiane T Takahashi, Olga A Dravolina, Irina Belozertseva, Edwin Zvartau, Anton Y Bespalov, Rainer Spanagel
RATIONALE: Preclinical studies suggest that the GABAB receptor is a potential target for treatment of substance use disorders. However, recent clinical trials report adverse effects in patients treated with the GABAB receptor agonist baclofen and even question efficacy. How can the discrepancy between preclinical and clinical findings be explained? OBJECTIVE: To test efficacy and adverse effects of baclofen and the novel GABAB positive allosteric modulator (PAM) CMPPE in rat addiction models, which were developed in accordance with DSM...
April 12, 2018: Psychopharmacology
https://www.readbyqxmd.com/read/29589877/an-observational-study-of-benzodiazepine-prescription-during-inpatient-alcohol-detoxification-for-patients-with-versus-without-chronic-pretreatment-with-high-dosage-baclofen
#3
EDITORIAL
https://www.readbyqxmd.com/read/29567624/functional-inactivation-of-the-orbitofrontal-cortex-disrupts-context-induced-reinstatement-of-alcohol-seeking-in-rats
#4
Paula Cristina Bianchi, Paulo Eduardo Carneiro de Oliveira, Paola Palombo, Rodrigo Molini Leão, Hugo Cogo-Moreira, Cleopatra da Silva Planeta, Fábio Cardoso Cruz
BACKGROUND: The high rate of relapse to drug use remains a central challenge to treating drug addiction. In human and rat models of addiction, environmental stimuli in contexts associated with previous drug use can provoke a relapse of drug seeking. Pre-clinical studies have used the ABA renewal procedure to study context-induced reinstatement of drug seeking. In the current study, we studied the role of the orbitofrontal cortex (OFC) in context-induced reinstatement to alcohol. METHODS: We trained male and female rats to self-administer alcohol in context A, extinguished drug-reinforced responding in a distinct context B, and assessed context-induced reinstatement in context A or B (control group)...
March 2, 2018: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29483088/baclofen-is-largely-ineffective-for-alcohol-use-disorders-finds-study
#5
Susan Mayor
No abstract text is available yet for this article.
February 26, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29479827/baclofen-its-effectiveness-in-reducing-harmful-drinking-craving-and-negative-mood-a-meta-analysis
#6
REVIEW
Abigail K Rose, Andrew Jones
BACKGROUND AND AIMS: There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a GABA-B agonist which is increasingly used as an off label treatment. A meta-analysis of randomised controlled trials (RCTs) was conducted to determine the efficacy of baclofen in reducing drinking behaviour, craving, depression, and anxiety, compared with placebo. METHODS: Random effects meta-analyses were computed on outcome data from 12 RCTs comparing baclofen with placebo...
February 26, 2018: Addiction
https://www.readbyqxmd.com/read/29359279/hypothalamic-pituitary-adrenocortical-axis-activity-in-alcohol-dependent-patients-during-treatment-with-high-dose-baclofen
#7
Olga Geisel, Ludwig Schlemm, Rainer Hellweg, Klaus Wiedemann, Christian A Müller
AIMS: Activity of the hypothalamic-pituitary-adrenocortical (HPA) axis has been reported to be affected in alcohol use disorder (AUD). It has been suggested that pharmacological relapse prevention in AUD might exert its effects partly by modulation of HPA axis activity. Here, we assessed the effects of high-dose treatment with baclofen on HPA axis activity in alcohol-dependent patients within a 24-week randomized, placebo-controlled trial (BACLAD study). METHODS: Plasma levels of copeptin, adrenocorticotropic hormone (ACTH), and cortisol were measured at 3 timepoints in alcohol-dependent patients during the study...
January 22, 2018: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29224234/an-observational-study-of-benzodiazepine-prescription-during-inpatient-alcohol-detoxification-for-patients-with-vs-without-chronic-pretreatment-with-high-dosage-baclofen
#8
Laura Martinez, Florence Vorspan, Xavier Declèves, Julien Azuar, Maeva Fortias, Franck Questel, Alexandra Dereux, Leslie Grichy, Hélène Barreteau, Frank Bellivier, Jean-Pierre Lépine, Vanessa Bloch
High-dose baclofen is prescribed as a maintenance treatment to reduce alcohol use in patients with alcohol use disorder. Nevertheless, some patients still have massive alcohol intakes and require inpatient alcohol withdrawal. To compare the oral dose of benzodiazepine prescribed to manage alcohol withdrawal symptoms in patients with vs. without steady-state pretreatment with high-dose baclofen. Retrospective chart review study. Prescribed benzodiazepine dose expressed in diazepam-equivalent was compared between groups...
December 10, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29143356/on-the-ground-application-of-the-temporary-recommendation-for-use-regulatory-measure-on-off-label-use-of-baclofen-for-alcohol-dependence-in-france-a-regional-survey-of-community-pharmacies
#9
Marine Auffret, Benjamin Rolland, Anne-Sylvie Caous, Louise Gaboriau, Sylvie Deheul, Régis Bordet, Sophie Gautier
The 'temporary recommendation for use' (TRU) is a French novel regulatory measure for off-label drug. The first TRU to be issued by the French drug agency (in March 2014) pertained to the off-label use of baclofen for alcohol dependence (AD). We performed a questionnaire-based survey of the on-the-ground application of the baclofen TRU among community pharmacies in northern France. A pharmacist from 70 of the 219 pharmacies contacted (response rate: 32.0%) completed the questionnaire. The mean ± standard deviation number of off-label baclofen prescriptions for AD was 2...
November 15, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29120249/alcohol-addiction-the-safety-of-available-approved-treatment-options
#10
REVIEW
Mariangela Antonelli, Anna Ferrulli, Luisa Sestito, Gabriele A Vassallo, Claudia Tarli, Carolina Mosoni, Maria M Rando, Antonio Mirijello, Antonio Gasbarrini, Giovanni Addolorato
Alcohol Use Disorders (AUD) is a leading cause of mortality and morbidity worldwide. At present disulfiram, naltrexone and acamprosate are approved for the treatment of AUD in U.S. and Europe. Nalmefene is approved in Europe and sodium oxybate is approved in Italy and Austria only. Baclofen received a 'temporary recommendation for use' in France. Areas covered: The safety of the above mentioned medications on liver, digestive system, kidney function, nervous system, pregnancy and lactation and their possible side effects are described and discussed...
February 2018: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/29091319/population-pharmacokinetics-of-oral-baclofen-at-steady-state-in-alcoholic-dependent-adult-patients
#11
Lucie Chevillard, Naomi Sabo, Michel Tod, Laurence Labat, Céline Chasport, Céline Chevaleyre, Florence Thibaut, Jérôme Barré, Julien Azuar, Franck Questel, Florence Vorspan, Vanessa Bloch, Frank Bellivier, Bernard Granger, Camille Barrault, Xavier Declèves
Baclofen has been proposed for few years to help treating alcohol-dependence at higher doses than those used in neurology. Baclofen pharmacokinetics has been previously well described at low oral or intravenous doses but remains poorly investigated with such high oral doses. We here describe dose regimens of baclofen in 143 alcohol-dependent-patients treated with steady-state oral doses of baclofen. Plasma baclofen levels were measured in blood samples using liquid chromatography coupled with tandem mass spectrometry...
November 1, 2017: Fundamental & Clinical Pharmacology
https://www.readbyqxmd.com/read/29050951/microinjection-of-baclofen-and-cgp7930-into-the-ventral-tegmental-area-suppresses-alcohol-self-administration-in-alcohol-preferring-rats
#12
REVIEW
Paola Maccioni, Irene Lorrai, Andrea Contini, Kimberly Leite-Morris, Giancarlo Colombo
Systemic administration of the orthosteric agonist, baclofen, and several positive allosteric modulators (PAMs) of the GABAB receptor has repeatedly been reported to decrease operant oral alcohol self-administration in rats. The aim of the present study was to evaluate the contribution of the mesolimbic dopamine system to the reducing effect of baclofen and GABAB PAMs on the reinforcing properties of alcohol. To this end, baclofen or the GABAB PAM CGP7930 were microinjected into the ventral tegmental area (VTA) of selectively bred, Sardinian alcohol-preferring (sP) rats trained to self-administer alcohol...
October 16, 2017: Neuropharmacology
https://www.readbyqxmd.com/read/29036310/baclofen-self-poisoning-in-the-era-of-changing-indication-multicentric-reports-to-a-french-poison-control-centre
#13
Maxime Léger, Marion Brunet, Gaël Le Roux, Nicolas Lerolle, David Boels
Aims: Baclofen has gained interest in treating alcohol use disorder patients. These patients are at risk of voluntary drug intoxications. Understanding the context of baclofen's widespread use for alcohol use disorder, a recent evaluation of the epidemiology, morbidity and mortality of baclofen self-poisoning episodes is necessary. Methods: All baclofen self-poisoning reported to the Western France Poison Control Centre between January 2008 and December 2015 were included for analysis in this retrospective study...
September 28, 2017: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/28967184/lc-ms-ms-method-for-quantification-of-baclofen-in-hair-a-useful-tool-to-assess-compliance-in-alcohol-dependent-patients
#14
I A Larabi, N Fabresse, A Knapp, M Forcet, F J Baud, G Lorin Grandmaison, J C Alvarez
In order to evaluate adherence to treatment, we developed and validated a novel LC-MS/MS method for baclofen quantification in hair. 20 mg were washed twice with dichloromethane, incubated in phosphate buffer (pH 5) for 10 min at 95°C, then extracted by liquid-liquid extraction in alkaline condition. Baclofen-d4 was used as internal standard. This method was applied to assess compliance in four treated alcohol dependent patients (3 dead and one alive). Blood quantification of baclofen and ethanol were performed in the 4 cases...
October 2, 2017: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28940866/pharmacologically-controlled-drinking-in-the-treatment-of-alcohol-dependence-or-alcohol-use-disorders-a-systematic-review-with-direct-and-network-meta-analyses-on-nalmefene-naltrexone-acamprosate-baclofen-and-topiramate
#15
REVIEW
Clément Palpacuer, Renan Duprez, Alexandre Huneau, Clara Locher, Rémy Boussageon, Bruno Laviolle, Florian Naudet
BACKGROUND AND AIMS: Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders (AUDs) is an emerging concept. Our objective was to explore the comparative effectiveness of drugs used in this indication. DESIGN: Systematic review with direct and network meta-analysis of double-blind randomized controlled trials (RCTs) assessing the efficacy of nalmefene, naltrexone, acamprosate, baclofen or topiramate in non-abstinent adults diagnosed with alcohol dependence or AUDs...
February 2018: Addiction
https://www.readbyqxmd.com/read/28939163/systematic-review-baclofen-dosing-protocols-for-alcohol-use-disorders-used-in-observational-studies
#16
REVIEW
Andrew Thompson, Lynn Owens, Paul Richardson, Munir Pirmohamed
The popularity of baclofen as an anti-craving agent in the treatment of alcohol use disorders (AUDs) has increased, especially in patients with established liver disease. However, evidence-based guidelines to inform practice are lacking. The aim of this systematic review is explore the prescribing practices of baclofen in AUD treatment. Electronic databases were searched for relevant articles from 2002. Assessment of eligibility criteria for inclusion was performed independently by two investigators. The main outcomes of interest were maximum dose, starting dose, titration regimen, effectiveness, and tolerability...
November 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28919445/cognitive-effects-of-labeled-addictolytic-medications
#17
REVIEW
Camille Noélie Pujol, Cecilia Paasche, Vincent Laprevote, Benoit Trojak, Pierre Vidailhet, Elisabeth Bacon, Laurence Lalanne
INTRODUCTION: Alcohol, tobacco, and illegal drug usage is pervasive throughout the world, and abuse of these substances is a major contributor to the global disease burden. Many pharmacotherapies have been developed over the last 50years to target addictive disorders. While the efficacy of these pharmacotherapies is largely recognized, their cognitive impact is less known. However, all substance abuse disorders are known to promote cognitive disorders like executive dysfunction and memory impairment...
September 14, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28827047/high-drinking-in-the-dark-hdid-mice-are-sensitive-to-the-effects-of-some-clinically-relevant-drugs-to-reduce-binge-like-drinking
#18
John C Crabbe, Angela R Ozburn, Pamela Metten, Amanda Barkley-Levenson, Jason P Schlumbohm, Stephanie E Spence, Wyatt R Hack, Lawrence C Huang
BACKGROUND: There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders - disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs)>0.08% during a period of approximately 2h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice...
September 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28822350/baclofen-for-alcohol-withdrawal
#19
REVIEW
Jia Liu, Lu-Ning Wang
BACKGROUND: Baclofen shows potential for rapidly reducing symptoms of severe alcohol withdrawal syndrome (AWS) in people with alcoholism. Treatment with baclofen is easy to manage and rarely produces euphoria or other pleasant effects, or craving for the drug. This is an updated version of the original Cochrane Review published in 2015, Issue 4. OBJECTIVES: To assess the efficacy and safety of baclofen for people with AWS. SEARCH METHODS: We updated our searches of the following databases to March 2017: the Cochrane Drugs and Alcohol Group Specialised Register, CENTRAL, PubMed, Embase, and CINAHL...
August 20, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28755747/a-prospective-cohort-study-examining-the-effectiveness-of-baclofen-in-the-maintenance-of-abstinence-in-alcohol-use-disorder-patients-attending-a-joint-liver-and-alcohol-treatment-clinic
#20
Lynn Owens, Andrew Thompson, Abi Rose, Ian Gilmore, Munir Pirmohamed, Paul Richardson
OBJECTIVE: Alcohol-related liver disease (ARLD) is the leading cause of alcohol-related mortality in the UK. Helping patients with ARLD to stop drinking is an important treatment goal. The aim of this study is to explore baclofen's utility in maintaining abstinence. METHODS - A PROSPECTIVE COHORT STUDY: Patients with ARLD were commenced on baclofen; the dose was titrated according to tolerability and response up to 30 mg three times daily. Severity of physical dependence and biochemical markers of liver injury were assessed at baseline, 3 months, and 12 months...
August 2017: Alcohol
keyword
keyword
86358
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"